Loading...

Intrexon

NYSE:XON
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XON
NYSE
$2B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Intrexon Corporation operates in the synthetic biology field in the United States. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print Invest
  • Intrexon has significant price volatility in the past 3 months.
XON Share Price and Events
Price Volatility
XON
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Intrexon undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Intrexon. This is due to cash flow or dividend data being unavailable. The share price is $13.74.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Intrexon's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Intrexon's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NYSE:XON PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in USD $-1.43
NYSE:XON Share Price ** NYSE (2018-08-15) in USD $13.74
United States of America Biotechs Industry PE Ratio Median Figure of 70 Publicly-Listed Biotechs Companies 26.97x
United States of America Market PE Ratio Median Figure of 7,193 Publicly-Listed Companies 18.22x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Intrexon.

NYSE:XON PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:XON Share Price ÷ EPS (both in USD)

= 13.74 ÷ -1.43

-9.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intrexon is loss making, we can't compare its value to the US Biotechs industry average.
  • Intrexon is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Intrexon's expected growth come at a high price?
Raw Data
NYSE:XON PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.59x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
44.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 52 Publicly-Listed Biotechs Companies 1.72x
United States of America Market PEG Ratio Median Figure of 5,693 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

NYSE:XON PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -9.59x ÷ 44.4%

-0.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intrexon is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Intrexon's assets?
Raw Data
NYSE:XON PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in USD $4.25
NYSE:XON Share Price * NYSE (2018-08-15) in USD $13.74
United States of America Biotechs Industry PB Ratio Median Figure of 565 Publicly-Listed Biotechs Companies 4.26x
United States of America Market PB Ratio Median Figure of 11,718 Publicly-Listed Companies 1.87x
NYSE:XON PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:XON Share Price ÷ Book Value per Share (both in USD)

= 13.74 ÷ 4.25

3.23x

* Primary Listing of Intrexon.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intrexon is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Intrexon's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Intrexon has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Intrexon expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
44.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Intrexon expected to grow at an attractive rate?
  • Unable to compare Intrexon's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Intrexon's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Intrexon's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NYSE:XON Future Growth Rates Data Sources
Data Point Source Value (per year)
NYSE:XON Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 44.4%
NYSE:XON Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 8.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 20.8%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 6.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NYSE:XON Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NYSE:XON Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31
2019-12-31 214 -86 3
2018-12-31 160 -55 -175 1
NYSE:XON Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-06-30 208 -114 -179
2018-03-31 217 -109 -132
2017-12-31 231 -104 -117
2017-09-30 200 -94 -134
2017-06-30 203 -88 -123
2017-03-31 201 -77 -154
2016-12-31 191 -56 -187
2016-09-30 186 -19 -175
2016-06-30 191 49 -184
2016-03-31 183 45 -176
2015-12-31 174 36 -84
2015-09-30 163 14 -33

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Intrexon is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Intrexon's revenue is expected to grow by 8.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NYSE:XON Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Intrexon Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:XON Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31 -0.97 -0.65 -1.29 2.00
2018-12-31 -1.36 -1.36 -1.36 1.00
NYSE:XON Past Financials Data
Date (Data in USD Millions) EPS *
2018-06-30 -1.43
2018-03-31 -1.08
2017-12-31 -0.98
2017-09-30 -1.12
2017-06-30 -1.04
2017-03-31 -1.30
2016-12-31 -1.58
2016-09-30 -1.49
2016-06-30 -1.59
2016-03-31 -1.55
2015-12-31 -0.76
2015-09-30 -0.31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Intrexon will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Intrexon's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Intrexon has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Intrexon performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Intrexon's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Intrexon does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Intrexon's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Intrexon's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Intrexon's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Intrexon Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:XON Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 207.99 -178.50 148.36
2018-03-31 216.90 -131.78 152.51
2017-12-31 230.98 -117.02 147.68
2017-09-30 199.96 -133.89 148.10
2017-06-30 202.92 -123.18 142.64
2017-03-31 201.24 -153.58 134.32
2016-12-31 190.93 -186.61 138.07
2016-09-30 186.42 -175.19 137.43
2016-06-30 190.80 -184.42 125.00
2016-03-31 183.19 -176.02 118.33
2015-12-31 173.61 -84.49 106.73
2015-09-30 163.20 -32.95 91.67
2015-06-30 131.03 -47.46 84.77
2015-03-31 97.93 -58.84 76.23
2014-12-31 71.93 -81.82 62.52
2014-09-30 47.98 -112.86 53.40
2014-06-30 32.83 -51.81 45.96
2014-03-31 27.73 -10.54 38.71
2013-12-31 23.76 -57.37 33.25
2013-09-30 23.12 -81.81 25.78
2013-06-30 20.01 -116.09 23.79
2013-03-31 16.04 -127.21 22.32
2012-12-31 13.77 -103.87 23.60
2011-12-31 8.01 -99.15 17.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Intrexon has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Intrexon has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Intrexon improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Intrexon's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Intrexon has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Intrexon's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Intrexon's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Intrexon is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Intrexon's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Intrexon's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 17.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Intrexon Company Filings, last reported 1 month ago.

NYSE:XON Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 567.14 8.34 81.13
2018-03-31 571.43 8.25 123.50
2017-12-31 546.55 8.27 79.67
2017-09-30 553.18 8.35 108.72
2017-06-30 571.55 8.40 157.16
2017-03-31 550.16 8.41 205.23
2016-12-31 569.25 8.77 237.21
2016-09-30 608.42 8.97 236.55
2016-06-30 628.18 8.48 270.75
2016-03-31 674.83 9.04 260.39
2015-12-31 704.89 9.09 238.31
2015-09-30 729.62 9.59 216.30
2015-06-30 486.93 10.34 166.33
2015-03-31 653.35 10.35 181.48
2014-12-31 409.29 12.64 115.96
2014-09-30 379.84 11.47 123.08
2014-06-30 388.37 2.00 175.55
2014-03-31 431.90 1.81 222.81
2013-12-31 381.34 1.69 177.49
2013-09-30 391.21 2.57 197.89
2013-06-30 206.33 2.35 129.92
2013-03-31 127.74 2.29 60.00
2012-12-31 85.11 0.09 10.66
2011-12-31 80.42 0.17 19.89
  • Intrexon's level of debt (1.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1.1% vs 1.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Intrexon has sufficient cash runway for 1.3 years based on current financial obligations.
  • Intrexon has sufficient cash runway for 1.7 years if financial obligations continue to grow at historical rates of 63.2% each year.
X
Financial health checks
We assess Intrexon's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Intrexon has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Intrexon's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Intrexon dividends.
If you bought $2,000 of Intrexon shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Intrexon's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Intrexon's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NYSE:XON Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 17 Stocks 1.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 5588 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NYSE:XON Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Intrexon has not reported any payouts.
  • Unable to verify if Intrexon's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Intrexon's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Intrexon has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Intrexon's dividends in 3 years as they are not expected to pay a notable for United States of America.
X
Income/ dividend checks
We assess Intrexon's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Intrexon afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Intrexon has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Intrexon's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
RJ Kirk, image provided by Google.
RJ Kirk
COMPENSATION $1,907,879
AGE 65
TENURE AS CEO 9.3 years
CEO Bio

Mr. Randal J. Kirk, also known as RJ, J.D., has been the Chief Executive Officer of Intrexon Corporation since April 2009. Mr. Kirk served as President of Intrexon Corporation since April 2009. He served as Acting President of Human Therapeutics Division at Intrexon Corporation until June 2011. Mr. Kirk serves as a Senior Managing Director, Chief Executive Officer and Chairman of Third Security, LLC. He founded the firm in March 1999. Mr. Kirk has been a Manager at New River Management Company, LLC since 1996. He served as the President and Chief Executive Officer at New River Pharmaceuticals Inc. from October 2001 and April 2007. Mr. Kirk founded New River Pharmaceuticals Inc. in 1996. He began his professional career in the private practice of law. Mr. Kirk co-founded General Injectables & Vaccines, Inc. in 1984. He also co-founded King Pharmaceuticals, Inc. in 1993. He has been the Chairman of the Board at New River Pharmaceuticals Inc. since 1996 and a Director since August 1996. He has been the Chairman of Landmark Scientific, Inc. since 1996. Mr. Kirk serves as the Chairman of Biological & Popular Culture LLC since September 2002 and the Chairman of its predecessor from October 1999 to September 2002. He has been the Chairman of Intrexon Corporation since February 2008 and Cyntellect Inc. since September 2008. He is a member of the Board of Directors of the Edward Via College of Osteopathic Medicine since May 2015. He has been a Director of Michael W. Cook Asset Management, Inc. since January 2003. He has been a Director of Intrexon Corporation since 2008. He has been a Director at Harvest Pharmaceuticals Inc. since December 2002 and ZIOPHARM Oncology, Inc. since January 12, 2011. He was an Independent Director of Halozyme Therapeutics, Inc. since May 2007 until March 2018. He has served on the Virginia Bioinformatics Institute Policy Advisory Board since March 2004. He served as the Chairman of Board for Clinical Data since December 16, 2004 and April 2011. Mr. Kirk served as the Chairman of the Board at GIV prior to the sale of that company in 1998. Mr. Kirk served as the Director of Clinical Data from September 2002 to April 2011. He served as a Director of Scios Inc. from February 2000 until his resignation on May 15, 2002 and Howe and Rusling, Inc. from December 2001 to 2006. He was on the Governor's Economic Development and Jobs Creation Commission from April 2010 to October 2012. He had been a Member to the Board of Visitors at University of Virginia and Affiliated Schools from July 20, 2009 to October 2012. He served as a member of the Board of Directors of the Virginia University Research Partnership from July 2007 to November 2010. Mr. Kirk served on the Board of Visitors of Radford University since July 2003 to June 2009 and was elected Rector of the Board from September 2006 to September 2008. He Kirk served as a Director of the Radford University Foundation, Inc. from September 1998 to May 2011. He was appointed to the Virginia Advisory Council on Revenue Estimates from July 2006 to October 2012. Mr. Kirk received a JD from the University of Virginia and a BA in Business from Radford University.

CEO Compensation
  • RJ's compensation has been consistent with company performance over the past year.
  • RJ's compensation is higher than average for a company of this size and profit level.
Management Team Tenure

Average tenure and age of the Intrexon management team in years:

7.6
Average Tenure
54
Average Age
  • The average tenure for the Intrexon management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

RJ Kirk

TITLE
Chairman & CEO
COMPENSATION
$2M
AGE
65
TENURE
9.3 yrs

Rick Sterling

TITLE
Chief Financial Officer
COMPENSATION
$3M
AGE
54
TENURE
11.6 yrs

Don Lehr

TITLE
Chief Legal Officer & Corporate Secretary
COMPENSATION
$3M
AGE
43
TENURE
7.6 yrs

Bob Walsh

TITLE
Senior Vice President of Energy & Fine Chemicals Platforms
COMPENSATION
$3M
AGE
60
TENURE
5.3 yrs

Jeff Perez

TITLE
Senior Vice President of Intellectual Property Affairs
COMPENSATION
$3M
AGE
46
TENURE
4 yrs

Thomas Reed

TITLE
Founder & Chief Science Officer
COMPENSATION
$573K
AGE
52
TENURE
20.6 yrs

Tom Bostick

TITLE
Chief Operating Officer
AGE
61
TENURE
0.8 yrs

Chris Basta

TITLE
Vice President of Investor Relations

Darryl Webster

TITLE
Senior Vice President of Intellectual Property
AGE
58
TENURE
8.6 yrs

Nir Nimrodi

TITLE
Chief Business Officer
COMPENSATION
$521K
AGE
49
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Intrexon board of directors in years:

8.1
Average Tenure
63
Average Age
  • The tenure for the Intrexon board of directors is about average.
Board of Directors

Cesar Alvarez

TITLE
Independent Director
COMPENSATION
$256K
AGE
70
TENURE
10.5 yrs

RJ Kirk

TITLE
Chairman & CEO
COMPENSATION
$2M
AGE
65
TENURE
10.5 yrs

Jeff Kindler

TITLE
Independent Director
COMPENSATION
$256K
AGE
62
TENURE
6.8 yrs

Jim Turley

TITLE
Independent Director
COMPENSATION
$251K
AGE
63
TENURE
4.3 yrs

Robert Shapiro

TITLE
Lead Independent Director
COMPENSATION
$251K
AGE
79

Steven Frank

TITLE
Independent Director
COMPENSATION
$241K
AGE
58
TENURE
10.5 yrs

Dean Mitchell

TITLE
Independent Director
COMPENSATION
$251K
AGE
62
TENURE
9.4 yrs

Fred Hassan

TITLE
Director
COMPENSATION
$241K
AGE
72
TENURE
2.2 yrs

Vinita Gupta

TITLE
Director
COMPENSATION
$713K
AGE
50
TENURE
1.3 yrs
Recent Insider Trading
  • No 3 month insider trading information.
Who owns this company?
X
Management checks
We assess Intrexon's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap and profit (greater than 0.5% of the company's profit + 0.03% of market cap)? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Intrexon has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Why Intrexon Corporation (NYSE:XON) Is A Financially Healthy Company

Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Intrexon Corporation (NYSE:XON), with a market cap of US$2.20b, often get neglected by retail investors. … Despite this, the two other categories have lagged behind the risk-adjusted returns of commonly ignored mid-cap stocks. … Today we will look at XON’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth.

Simply Wall St -

Intrexon Corporation's (NYSE:XON) Shift From Loss To Profit

Many investors are wondering the rate at which XON will turn a profit, with the big question being “when will the company breakeven?” In this article, I will touch on the expectations for XON’s growth and when analysts expect the company to become profitable. … Working backwards from analyst estimates, it turns out that they expect the company to grow 56.83% year-on-year, on average, which signals high confidence from analysts. … Next Steps: This article is not intended to be a comprehensive analysis on XON, so if you are interested in understanding the company at a deeper level, take a look at XON’s company page on Simply Wall St.

Simply Wall St -

Has Intrexon Corporation (NYSE:XON) Improved Earnings Growth In Recent Times?

After reading Intrexon Corporation's (NYSE:XON) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … View our latest analysis for Intrexon Commentary On XON's Past Performance I like to use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … This shows that, Intrexon has historically performed better than recently, though it seems like earnings are now heading back towards a more favorable position once more.

Simply Wall St -

What Do Intrexon Corporation (XON) Insiders Know That You Don't?

Today we will evaluate whether these decisions are bolstered by analysts’ expectations of future growth as well as recent share price movements. … NYSE:XON Future Profit Nov 10th 17 On the surface, analysts’ revenue growth projection of 171.60% over the next three years provides a very optimistic outlook for the business which is consistent with the signal company insiders are sending with their net buying activity. … Next Steps: XON’s insider meaningful buying activity tells us the shares are currently in favour, which is coherent with the positive growth in expected earnings, and a fairly high volatility in share price over the same time period.

Simply Wall St -

Company Info

Map
Description

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Details
Name: Intrexon Corporation
XON
Exchange: NYSE
Founded: 1998
$1,943,914,720
136,991,876
Website: http://www.dna.com
Address: Intrexon Corporation
20374 Seneca Meadows Parkway,
Germantown,
Maryland, 20876,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE XON Common Stock New York Stock Exchange US USD 08. Aug 2013
DB I5X Common Stock Deutsche Boerse AG DE EUR 08. Aug 2013
Number of employees
Current staff
Staff numbers
956
Intrexon employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/08/15 23:46
End of day share price update: 2018/08/15 00:00
Last estimates confirmation: 2018/08/13
Last earnings update: 2018/06/30
Last annual earnings update: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.